Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort ascending
Jul
27
2020
In Response to COVID-19, FDA Extends Enforcement Discretion for HCT/Ps Requiring Pre-Market Review Epstein Becker & Green, P.C.
Sep
25
2020
Deadline Looms for Responding to DEA’s Proposed Aggregate Production Quotas for 2021 Epstein Becker & Green, P.C.
Mar
26
2024
Last Call for Comments on the Bipartisan Discussion Draft of the SUSTAIN Act: Shaping 340B for the Future Epstein Becker & Green, P.C.
May
10
2017
Commissioner Scott Gottlieb’s Priorities as Newly Approved FDA Commissioner Epstein Becker & Green, P.C.
Apr
7
2021
#WorkforceWednesday: Action Pending from Biden’s OFCCP and OSHA Epstein Becker & Green, P.C.
Jun
3
2021
Federal and State Cannabis Rules Are Moving in Different Directions – Diagnosing Health Care [PODCAST] Epstein Becker & Green, P.C.
Jun
25
2018
Cheers to 80 Years: Celebrating the Anniversary of the Federal Food, Drug, and Cosmetic Act Epstein Becker & Green, P.C.
Dec
16
2021
CMS Issues Guidance on COVID-19 Testing in the Workplace Epstein Becker & Green, P.C.
May
23
2019
The Role of Patient Preference in Medical Device Evaluation Epstein Becker & Green, P.C.
Aug
1
2023
FDA’s LDT Proposed Rule Heads to the White House Epstein Becker & Green, P.C.
Sep
5
2023
State Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of Oklahoma PBM Law Epstein Becker & Green, P.C.
Nov
20
2023
Sharing Scientific Information with HCPs on Unapproved Uses of Medical Products: Dos and Don’ts Under FDA’s New Draft Guidance Epstein Becker & Green, P.C.
Mar
7
2024
Making Moves – FDA’s LDT Proposed Rule Sent to OMB for Review Epstein Becker & Green, P.C.
Apr
20
2018
DEA Proposed Rule Would Limit Drug Manufacturer’s Annual Opioid Production Epstein Becker & Green, P.C.
Dec
11
2018
FDA to Overhaul Medical Device Approval Process Epstein Becker & Green, P.C.
Jan
22
2019
Not Business as Usual: The Government Shutdown’s Impact at FDA Epstein Becker & Green, P.C.
Jun
22
2022
The Pendulum Swings Both Ways: State Responses to Protect Reproductive Health Data, Post-Roe Epstein Becker & Green, P.C.
Jul
1
2019
Nevada Becomes First State to Prohibit Rejection of Applicants Testing Positive for Marijuana Epstein Becker & Green, P.C.
May
7
2015
CMS Amends Medicare Part D Program Integrity Regulations to Facilitate Beneficiary Access and Expand Coverage for Pharmacist Prescribers Epstein Becker & Green, P.C.
Mar
7
2023
The Wait is Over . . . Or Is It? DEA’s Proposed Rules Around Telemedicine Prescribing: Initial Impressions and Key Takeaways Epstein Becker & Green, P.C.
Apr
4
2023
Unpacking Averages: FDA FOIA Response Times by Topic of Request Epstein Becker & Green, P.C.
May
9
2023
Podcast: The Legal Battle Over Mifepristone – Diagnosing Health Care [PODCAST] Epstein Becker & Green, P.C.
Jun
21
2023
Video: Employee and Health Benefits One Year After Dobbs – Employment Law This Week Epstein Becker & Green, P.C.
Mar
19
2020
Families First Coronavirus Response Act: Guidance for Health Care Providers and Plans Regarding COVID-19 Epstein Becker & Green, P.C.
Sep
5
2023
FDA Issues Final Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors Epstein Becker & Green, P.C.
Nov
18
2016
Chicago Imposes Burdensome New Licensure and Disclosure Obligations on Pharmaceutical Representatives Epstein Becker & Green, P.C.
Jan
20
2017
FDA Says Yes to Pre-Approval Communications with Payors but Reaffirms its Approach to Restrictions on Off-Label Communications Epstein Becker & Green, P.C.
Feb
2
2017
FDA Adopts New Designation Process for Regenerative Advanced Therapies Epstein Becker & Green, P.C.
Mar
19
2024
FDA and OHRP Issue Joint Draft Guidance on Content, Organization, and Presentation of Consent Forms for Research Participants Epstein Becker & Green, P.C.
Dec
17
2020
EEOC Updates COVID-19 Guidance on Employer Administered or Mandated Vaccinations Epstein Becker & Green, P.C.
Feb
8
2018
Letter from U.S. Senators Applies Additional Pressure to DEA to Promulgate “Special Registration” Rules Under the Ryan Haight Act Epstein Becker & Green, P.C.
Sep
4
2015
Wine Seller Victory in Illinois Qui Tam Lawsuit Horwood Marcus & Berk Chartered
May
19
2022
Expert Witness Case Complexity & Vetting – Episode 36 [Podcast] IMS Legal Strategies
Dec
1
2022
Chemical Engineering Trends, Intellectual Property Litigation, & Industry Predictions – Episode 50 [PODCAST] IMS Legal Strategies
Aug
14
2015
U.S. v. Bayer Is Proof ─ Daubert Is Not Hard To Digest IMS Legal Strategies
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins